Literature DB >> 22302104

Osteocyte regulation of bone mineral: a little give and take.

G J Atkins1, D M Findlay.   

Abstract

Osteocytes actively participate in almost every phase of mineral handling by bone. They regulate the mineralisation of osteoid during bone formation, and they are also a major RANKL-producing cell. Osteocytes are thus able to liberate bone mineral by regulating osteoclast differentiation and activity in response to a range of stimuli, including bone matrix damage, bone disuse and mechanical unloading, oestrogen deficiency, high-dose glucocorticoid and chemotherapeutic agents. At least some of these activities may be regulated by the osteocyte-secreted product, sclerostin. There is also mounting evidence that in addition to regulating phosphate homeostasis systemically, osteocytes contribute directly to calcium homeostasis in the mature skeleton. Osteocyte cell death and the local loss of control of bone mineralisation may be the cause of focal hypermineralisation of bone and osteopetrosis, as seen in aging and pathology. The sheer number of osteocytes in bone means that "a little give and take" in terms of regulation of bone mineral content translates into a powerful whole organism effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302104     DOI: 10.1007/s00198-012-1915-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  127 in total

1.  Response of the osteocyte syncytium adjacent to and distant from linear microcracks during adaptation to cyclic fatigue loading.

Authors:  S A Colopy; J Benz-Dean; J G Barrett; S J Sample; Y Lu; N A Danova; V L Kalscheur; R Vanderby; M D Markel; P Muir
Journal:  Bone       Date:  2004-10       Impact factor: 4.398

2.  DNA fragmentation during bone formation in neonatal rodents assessed by transferase-mediated end labeling.

Authors:  A L Bronckers; W Goei; G Luo; G Karsenty; R N D'Souza; D M Lyaruu; E H Burger
Journal:  J Bone Miner Res       Date:  1996-09       Impact factor: 6.741

3.  The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption--bone flow theory.

Authors:  A M Parfitt
Journal:  Clin Orthop Relat Res       Date:  1977       Impact factor: 4.176

4.  Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia.

Authors:  K N Fedde; L Blair; J Silverstein; S P Coburn; L M Ryan; R S Weinstein; K Waymire; S Narisawa; J L Millán; G R MacGregor; M P Whyte
Journal:  J Bone Miner Res       Date:  1999-12       Impact factor: 6.741

5.  Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis.

Authors:  B Y Chan; E S Fuller; A K Russell; S M Smith; M M Smith; M T Jackson; M A Cake; R A Read; J F Bateman; P N Sambrook; C B Little
Journal:  Osteoarthritis Cartilage       Date:  2011-05-12       Impact factor: 6.576

6.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

Review 7.  The wrickkened pathways of FGF23, MEPE and PHEX.

Authors:  Peter S N Rowe
Journal:  Crit Rev Oral Biol Med       Date:  2004-09-01

Review 8.  Bone mineralization density distribution in health and disease.

Authors:  P Roschger; E P Paschalis; P Fratzl; K Klaushofer
Journal:  Bone       Date:  2007-11-12       Impact factor: 4.398

9.  Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Authors:  Xiaodong Li; Michael S Ominsky; Qing-Tian Niu; Ning Sun; Betsy Daugherty; Diane D'Agostin; Carole Kurahara; Yongming Gao; Jin Cao; Jianhua Gong; Frank Asuncion; Mauricio Barrero; Kelly Warmington; Denise Dwyer; Marina Stolina; Sean Morony; Ildiko Sarosi; Paul J Kostenuik; David L Lacey; W Scott Simonet; Hua Zhu Ke; Chris Paszty
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

10.  The influence of mechanical stimulation on osteocyte apoptosis and bone viability in human trabecular bone.

Authors:  V Mann; C Huber; G Kogianni; D Jones; B Noble
Journal:  J Musculoskelet Neuronal Interact       Date:  2006 Oct-Dec       Impact factor: 2.041

View more
  48 in total

1.  Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.

Authors:  Y Asamiya; A Yajima; S Shimizu; S Otsubo; K Tsuchiya; K Nitta
Journal:  Osteoporos Int       Date:  2014-11-04       Impact factor: 4.507

Review 2.  Current Status of Bone-Forming Therapies for the Management of Osteoporosis.

Authors:  Anne Sophie Koldkjær Sølling; Torben Harsløf; Bente Langdahl
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 3.  Periprosthetic osteolysis after total hip replacement: molecular pathology and clinical management.

Authors:  Donald W Howie; Susan D Neale; David R Haynes; Oksana T Holubowycz; Margaret A McGee; Lucian B Solomon; Stuart A Callary; Gerald J Atkins; David M Findlay
Journal:  Inflammopharmacology       Date:  2013-10-15       Impact factor: 4.473

4.  Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure.

Authors:  Michael P Whyte; Rattana Leelawattana; William R Reinus; Chang Yang; Steven Mumm; Deborah V Novack
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

5.  Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.

Authors:  Viviane Barcellos Menon; Rosa Maria Affonso Moysés; Samirah Abreu Gomes; Aluizio Barbosa de Carvalho; Vanda Jorgetti; Ita Pfeferman Heilberg
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

Review 6.  Role of cortical bone in hip fracture.

Authors:  Jonathan Reeve
Journal:  Bonekey Rep       Date:  2017-01-13

Review 7.  The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Anne Sophie Koldkjær Sølling; Torben Harsløf; Bente Langdahl
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-06-07       Impact factor: 5.346

8.  A novel large fragment deletion in PLS3 causes rare X-linked early-onset osteoporosis and response to zoledronic acid.

Authors:  F Lv; M Ma; W Liu; X Xu; Y Song; L Li; Y Jiang; O Wang; W Xia; X Xing; Z Qiu; M Li
Journal:  Osteoporos Int       Date:  2017-06-16       Impact factor: 4.507

Review 9.  Musculoskeletal Health in the Context of Spinal Cord Injury.

Authors:  Jillian M Clark; David M Findlay
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

Review 10.  Osteocytogenesis: Roles of Physicochemical Factors, Collagen Cleavage, and Exogenous Molecules.

Authors:  Xuening Chen; Lichen Wang; Kaitao Zhao; Hongjun Wang
Journal:  Tissue Eng Part B Rev       Date:  2018-01-05       Impact factor: 6.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.